Abbott Laboratories ABT
Abbott Laboratories (NYSE: ABT) is a drug developer. Its lead program is marketed.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Recent results and decisions
- Sep 30, 2026approval FDA approved TactiFlex Duo Ablation Catheter designed to deliver pulsed field and radiofrequency ablation for atrial fibrillation.
In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver both pulsed field ablation (PFA) and radiofrequency (RF) energy to treat patients battling atrial fibrillation.
Filing - Sep 30, 2026approval Abbott launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age 45 and older.
In September, Abbott launched SimpleScreen™ CRC, an FDA-approved, blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease.
Filing - Sep 1, 2026approval Abbott announced FDA approval for its TactiFlex Duo Ablation Catheter to deliver PFA and RF energy for atrial fibrillation treatment.
In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver both pulsed field ablation (PFA) and radiofrequency (RF) energy to treat patients battling atrial fibrillation.
Filing
9 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.